CYAD - Celyad Oncology: Chance To Get In Early And Cheap

• Celyad Oncology's technology, although still under development, has exciting possibilities, including the simplification of design and development of future therapy candidates, which could make therapies available 'off the shelf'.
• There is no getting around the fact that CYAD's product line up, while not shallow, is still in early to mid-stages of development.
• The company's technology platform has features that differentiate it considerably from other peers in the immunotherapy space, and will likely translate into sustained, long-term advantages.

For further details see: